Bio-Rad Laboratories Inc
NYSE: BIO · HEALTHCARE · MEDICAL DEVICES
Updated 2026-06-05
Bio-Rad Laboratories Inc (BIO) Financial statements
SEC filings — annual and quarterly data.
Margin trends — annual
| Year | Revenue | Net income | Gross margin | Op. margin | Profit margin |
|---|---|---|---|---|---|
| 2006 | $1.27B | $103.26M | 55.93% | 11.47% | 8.11% |
| 2007 | $1.46B | $92.99M | 54.16% | 9.25% | 6.36% |
| 2008 | $1.76B | $89.51M | 54.55% | 10.37% | 5.07% |
| 2009 | $1.78B | $144.62M | 56.04% | 12.95% | 8.11% |
| 2010 | $1.93B | $185.49M | 56.64% | 14.74% | 9.63% |
| 2011 | $2.07B | $178.22M | 56.81% | 14.23% | 8.60% |
| 2012 | $2.07B | $169.23M | 56.11% | 12.76% | 8.18% |
| 2013 | $2.13B | $77.79M | 55.26% | 7.95% | 3.65% |
| 2014 | $2.18B | $88.84M | 54.18% | 6.90% | 4.08% |
| 2015 | $2.02B | $113.09M | 55.54% | 8.26% | 5.60% |
| 2016 | $2.07B | $28.13M | 55.03% | 2.57% | 1.36% |
| 2017 | $2.16B | $114.74M | 54.97% | 5.40% | 5.31% |
| 2018 | $2.29B | $361.00M | 53.46% | -4.74% | 15.76% |
| 2019 | $2.31B | $1.76B | 54.38% | 9.93% | 76.08% |
| 2020 | $2.55B | $3.81B | 56.48% | 16.55% | 149.83% |
| 2021 | $2.92B | $4.25B | 56.05% | 17.12% | 145.57% |
| 2022 | $2.80B | $-3.63B | 55.93% | 17.22% | -129.45% |
| 2023 | $2.67B | $-637.32M | 53.42% | 12.65% | -23.86% |
| 2024 | $2.57B | $-1.84B | 53.73% | 10.48% | -71.86% |
| 2025 | $2.58B | $759.90M | 52.01% | 10.47% | 29.42% |
Frequently asked questions
What is Bio-Rad Laboratories Inc's revenue?
Bio-Rad Laboratories Inc's trailing twelve-month revenue is $2.59B. Revenue is the top line the whole model builds on, and at this scale the question shifts from how fast it grows to whether margins hold as it compounds.
How profitable is BIO?
In its most recent fiscal year, BIO ran a gross margin of 52.01%, an operating margin of 10.47%, and a net margin of 29.42%. Margins this high mean most of each extra dollar of revenue drops through to profit, which is the signature of real pricing power.
How much free cash flow does BIO generate?
BIO produced $374.60M in free cash flow in its most recent fiscal year. Free cash flow is what is left after running and reinvesting in the business, and it is the cash that actually funds buybacks, dividends, and a stronger balance sheet.
Is BIO's balance sheet healthy?
BIO holds $531.80M in cash and equivalents against $1.20B in long-term debt, on $7.45B of shareholder equity. That debt is best read against the cash flow the business throws off each year.